Betula verrucosa is in clinical development for the treatment of adults with confirmed tree pollen allergy-induced moderate to severe rhinoconjunctivitis. Allergic rhinoconjunctivitis is an allergic disorder of the nose and resulting in a chronic, mostly eosinophilic, inflammation of the nasal mucosa and conjunctiva. When the conjunctiva is also involved, the term rhinoconjunctivitis is more accurate. This produces typical symptoms of sneezing, nasal itching, discharge (rhinorrhoea), and congestion.
Betula verrucosa is a sublingual allergy immunotherapy (SLIT) tablet indicated for the treatment of tree pollen allergy, because of its high degree of inhibition of the reaction caused by allergen extracts. As an immunotherapy, betula verrucosa offers the advantage of not just being symptomatic, but also inducing tolerance and so alters the natural course of the disease. If licensed, betula verrucosa will offer an additional treatment option for patients with confirmed tree pollen allergy-induced moderate to severe rhinoconjunctivitis.
Ravulizumab is currently in clinical development for the treatment of adults with generalised myasthenia gravis (gMG). gMG is a long-term autoimmune disorder where the body’s own immune system mistakenly attacks healthy cells in the neuromuscular junction (NMJ). The NMJ is a region where nerve cells transmit signals to muscle cells to result in muscle contraction. …